Literature DB >> 27605055

Salivary gland hybrid tumour revisited: could they represent high-grade transformation in a low-grade neoplasm?

Henrik Hellquist1, Alena Skalova2, Bahram Azadeh3.   

Abstract

Salivary gland hybrid tumour, first described in 1996, is a very rare neoplasm for which exact morphological criteria have not been universally agreed upon. In contrast, the concept of high-grade transformation (HGT) in salivary neoplasms has been widely accepted during the last decade, and the number of reported cases is rapidly increasing. A review of the literature revealed 38 cases of hybrid tumour reported in 22 publications. During approximately the same time period, well over 100 cases of HGT in salivary neoplasms have been reported. There are important histological similarities between hybrid tumours and salivary tumours with HGT. In the latter, containing one tumour component of low-grade malignancy and the other of high grade, the two tumour components are not entirely separated and appear to originate in the same area. Virtually, all cases reported as hybrid tumour had no clear lines of demarcation between the two tumour types. We are inclined to suggest that most of the 38 cases of hybrid tumours described in the literature would today better be called tumour with HGT rather than hybrid tumour. The relative proportion of the two components may vary, and the high-grade component is sometimes very small, which emphasises the importance of very generous sampling of the surgical specimen. The molecular genetic mechanisms responsible for HGT, including what used to be called hybrid tumour, remain largely unknown. Abnormalities of a few genes (including p53, C-MYC, cyclin D1, HER-2/neu) have been documented. As insufficient data exist on gene abnormalities in these lesions, conclusions as to whether or not they have a common origin and which mechanisms are involved in transformation cannot be drawn. Due to the small number of cases reported, many of which lack follow-up details; indicators of prognosis of hybrid tumours are not available, but their behaviour seems to be similar to that of tumours with HGT, i.e. an accelerated aggressive course. HGT of salivary gland neoplasms greatly influences macroscopic and microscopic evaluation of the specimen but also, given the high incidence of metastases and morbidity, carries significant treatment implications.

Entities:  

Keywords:  Dedifferentiation; High-grade transformation; Hybrid tumour; Salivary gland neoplasms; Salivary glands

Mesh:

Year:  2016        PMID: 27605055     DOI: 10.1007/s00428-016-2018-6

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  75 in total

1.  Hybrid carcinomas of salivary glands.

Authors:  R Chetty; P Medley; A Essa
Journal:  Arch Pathol Lab Med       Date:  2000-04       Impact factor: 5.534

2.  Intercalated duct lesion of the parotid.

Authors:  Matthew R Naunheim; Harrison W Lin; William C Faquin; Derrick T Lin
Journal:  Head Neck Pathol       Date:  2012-01-22

3.  Dedifferentiated adenoid cystic carcinoma of the lacrimal gland.

Authors:  Joseph F Panarelli; Christopher I Zoumalan; Krishna Mukkamala; Elizabeth A Maher; Codrin Iacob; David A Della Rocca
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2011 Sep-Oct       Impact factor: 1.746

4.  Genetic profile of adenoid cystic carcinomas (ACC) with high-grade transformation versus solid type.

Authors:  Ana Flávia Costa; Albina Altemani; Hedy Vékony; Elisabeth Bloemena; Florentino Fresno; Carlos Suárez; José Luis Llorente; Mario Hermsen
Journal:  Cell Oncol (Dordr)       Date:  2011-05-04       Impact factor: 6.730

5.  Epithelial-myoepithelial carcinoma of the parotid gland with adenoid cystic carcinoma-like features: a case report with immunohistochemical study.

Authors:  K Hayashi; F Shimamoto; T Takata; W Yasui
Journal:  Hiroshima J Med Sci       Date:  2001-12

6.  Recurrent hyalinizing clear cell carcinoma of the base of tongue with high-grade transformation and EWSR1 gene rearrangement by FISH.

Authors:  Rongyu Jin; Kenneth J Craddock; Jonathan C Irish; Bayardo Perez-Ordonez; Ilan Weinreb
Journal:  Head Neck Pathol       Date:  2012-02-16

7.  Hybrid tumors or salivary gland tumors sharing common differentiation pathways? Reexamining adenoid cystic and epithelial-myoepithelial carcinomas.

Authors:  R T Grenko; C S Abendroth; A T Davis; R J Levin; I Dardick
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  1998-08

8.  Dedifferentiated acinic cell (acinous) carcinoma of the parotid gland.

Authors:  R J Stanley; L H Weiland; K D Olsen; B W Pearson
Journal:  Otolaryngol Head Neck Surg       Date:  1988-02       Impact factor: 3.497

9.  Combined acinic cell mucoepidermoid carcinoma of the parotid gland. Report of a case with immunohistochemical study.

Authors:  C Ballestin; M Lopez-Carreira; J I Lopez
Journal:  APMIS       Date:  1996-02       Impact factor: 3.205

10.  Dedifferentiation in adenoid cystic carcinoma.

Authors:  Radhika M Bavle; Sarah D'Mello; Soumya Makarla; Sreelatha S Hosthor
Journal:  J Oral Maxillofac Pathol       Date:  2013-09
View more
  3 in total

Review 1.  Development of head and neck pathology in Europe.

Authors:  Henrik Hellquist; Abbas Agaimy; Göran Stenman; Alessandro Franchi; Alfons Nadal; Alena Skalova; Ilmo Leivo; Nina Zidar; Roderick H W Simpson; Pieter J Slootweg; Juan C Hernandez-Prera; Alfio Ferlito
Journal:  Virchows Arch       Date:  2022-01-14       Impact factor: 4.064

2.  Coexistence of salivary duct, myoepithelial and epithelial-myoepithelial carcinomas in the parotid gland: a case report and literature review.

Authors:  Naoki Yanagawa; Masamichi Suzuki; Daisuke Saito; Ryo Sugimoto; Mitsumasa Osakabe; Noriyuki Uesugi; Kiyoto Shiga; Tamotsu Sugai
Journal:  J Surg Case Rep       Date:  2021-06-04

3.  An Unusual Hybrid Salivary Gland Tumor: Molecular Analysis Informs the Potential Pathogenesis of This Rare Neoplasm.

Authors:  Yan Zhou; Ernesto Martinez Duarte; David J Eleff; Laura J Tafe; Jason M Leibowitz; Darcy A Kerr
Journal:  Case Rep Pathol       Date:  2019-03-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.